Self-reactive T cell receptor-reactive CD8+ T cells inhibit T cell lymphoma growth in vivo

Journal of Immunology

Volumn 173, Issue 11, 2004, Pages 7062-7069

  Gonthier, Marie ^a   Llobera, Régine ^a   Arnaud, Jacques ^a   Rubin, Bent ^b  

^a CHU PURPAN   (France)

^b INSTITUT DE RECHERCHE PIERRE FABRE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 4; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MITOMYCIN C; T LYMPHOCYTE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; CELL FUNCTION; CELL GROWTH; CELL PROTECTION; CELLULAR IMMUNITY; DNA TRANSFECTION; EFFECTOR CELL; GROWTH INHIBITION; IMMUNE RESPONSE; IMMUNOPRECIPITATION; IN VIVO STUDY; LYMPHOMA CELL; MOUSE; MUTAGENESIS; NONHUMAN; PRIORITY JOURNAL; REACTIVE INHIBITION; T LYMPHOCYTE; TUMOR CELL;

EID: 9144265735     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.173.11.7062     Document Type: Article

References (40)

1. Rogers, P. R., and M. Croft. 1999. Peptide dose, affinity, and time of differentiation can contribute to the Th1/Th2 cytokine balance. J. Immunol. 163:1205.
2. Mosmann, T. R., and S. Sad. 1996. The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol. Today 17:138.
3. Davis, M. M., and P. Björkman. 1988. T-cell antigen receptor genes and T-cell recognition. Nature 334:395.
4. Toyonaga, B., and T. W. Mak. 1987. Genes of the T cell antigen receptor in normal and malignant T cells. Annu. Rev. Immunol. 5:585.
5. Bouneaud, C., P. Kourilsky, and P. Bousso. 2000. Impact of negative selection on the T cell repertoire reactive to a self-peptide: a large fraction of T cell clones escapes clonal deletion. Immunity 13:829.
6. Huseby, E. S., F. Crawford, J. White, J. Kappler, and P. Marrack. 2003. Negative selection imparts peptide specificity to the mature T cell repertoire. Proc. Natl. Acad. Sci. USA 100:11565.
7. Davis, S. J., S. Ikemizu, E. J. Evans, L. Fugger, T. R. Bakker, and P. A. van der Merve. 2003. The nature of molecular recognition by T cells. Nat. Immunol. 4:217.
8. Allison, J. P., B. W. McIntyre, and D. Bloch. 1982. Tumor-specific antigen of murine T lymphoma cells defined with monoclonal antibody. J. Immunol. 129:2293.
9. Staerz, U. D., M. S. Pasternack, J. R. Klein, J. D. Benedetto, and M. J. Bevan. 1983. Monoclonal antibodies specific for a murine cytotoxic T-lymphocyte clone. Proc. Natl. Acad. Sci. USA 81:1799.
10. Kaye, J., and C. A. Janeway, Jr. 1984. The Fab fragment of a directly activating monoclonal antibody that precipitates a disulfide-linked heterodimer from a helper T cell clone blocks activation by either allogeneic or antigen and self-Ia. J. Exp. Med. 159:1397.
11. Hua, C., M. Buferne, and A. M. Schmitt-Verhulst. 1985. Lysis of hybridoma cells bearing anti-clonotypic surface immunoglobulin by clonotype-expressing alloreactive cytotoxic T cells. Eur. J. Immunol. 15:1029.
12. Marchalonis, J. J., S. Kaveri, S. Lacroix-Desmazes, and M. D. Kazatchkine. 2002. Natural recognition repertoire and the evolutionary emergence of the combinatorial immune system. FASEB J. 16:842.
13. Jesson, M. I., U. McKeever, S. Khandekar, J. Newcomb, J. Naylor, P. Gregory, P. Brauer, B. Bettencourt, J. Banerji, and B. Jones. The immune response to soluble D10 TCR analysis of antibody and T cell responses. 1998. Int. Immunol. 10:27.
14. Kuhröber, A., R. Schirmbeck, and J. Reimann. 1994. Vaccination with T cell receptor peptides primes anti-receptor cytotoxic T lymphocytes (CTL) and anergizes T cells specifically recognized by these CTL. Eur. J. Immunol. 24:1172.
15. Thirdborough, S. M., J. N. Radcliffe, P. S. Friedmann, and F. K. Stevenson. 2002. Vaccination with DNA encoding a single-chain TCR fusion protein induces anti-clonotypic immunity and protects against T-cell lymphoma. Cancer Res. 62:1757.
16. Kumar, V., and E. E. Sercarz. 2001. An integrated model of regulation centered on recognition of TCR peptide/MHC complexes. Immunol. Rev. 181:113.
17. Cresswell, P., N. Bangia, T. Dick, and G. Diedrich. 1999. The nature of the MHC class I peptide loading complex. Immunol. Rev. 172:21.
18. Reimann, J., and R. Schirmbeck. 1999. Alternative pathways for processing exogenous and endogenous antigens that can generate peptides for MHC class I-restricted presentation. Immunol. Rev. 172:131.
19. Braciak, T. A., B. Pedersen, J. Chin, C. Hsiao, E. S. Ward, I. Maricic, A. Jahng, F. L. Graham, J. Gauldie, E. E. Sercarz, and V. Kumar. 2003. Protection against experimental autoimmune encephalomyelitis generated by a recombinant adenovirus vector expressing the Vβ8.2 TCR is disrupted by coadministration with vectors expressing either IL-4 or IL-10. J. Immunol. 170:765.
20. Madakamutil, L. T., I. Maricic, E. E. Sercarz, and V. Kumar. 2003. Regulatory T cells control autoimmunity in vivo by inducing apoptotic depletion of activated pathogenic lymphocytes. J. Immunol. 170:2985.
21. + cells in T cell receptor peptide-induced clonal unresponsiveness. Science 259:91.
22. + T cells in EAE mice. Proc. Natl. Acad. Sci. USA 167:6301.
23. Rubin, B., Y. Diaz de Durana, N. Li, and E. E. Sercarz. 2003. Regulator T cells: specific for antigen and/or antigen receptors? Scand. J. Immunol. 57:399.
24. Rubin, B., M. Gonthier, R. Llobera, and J. Arnaud. 2004. Two discrete functions of T cell antigen receptors in regulation of autoimmunity: Ligands and receptors. Curr. Trends Immunol. 31:259.
25. Wegener, A. M. K., B. Holm, C. Geisler, and B. Rubin. 1990. Cellular and molecular characteristics of transformed T-cells from antigen-specific T cell line. Scand. J. Immunol. 31:645.
26. Karasuyama, H., and F. Melchers. 1988. Establishment of mouse cell lines which constitutively secrete large quantities of interleukins 2, 3, 4 or 5 using modified cDNA expression vectors. Eur. J. Immunol. 18:97.
27. Arnaud, J., C. Cayrou, R. Llobera, and B. Rubin. 1997. Mutation in splicing consensus sequences causes lack of TCR membrane expression due to exon excision. Immunogenetics 45:311.
28. Rubin, B., and A. Boned. 1986. Insulin-specific T cell help to TNP-specific B cells requires activation via the antigen T cell receptor. Eur. J. Immunol. 16:1223.
29. Franco, A., D. A. Tilly, I. Gramaglia, M. Croft, L. Cipolla, M. Meldal, and H. M. Grey. 2000. Epitope affinity for MHC class I determines helper requirement for CTL priming. Nat. Immunol. 1:145.
30. Gouaillard, C., A. Huchenq-Champagne, J. Arnaud, C. H. Chen, and B. Rubin. 2001. Evolution of T cell receptor (TCR) αβ heterodimer assembly with the CD3 complex. Eur. J. Immunol. 31:3798.
31. Arnaud, J., M. Erard, E. Martin, R. Llobera, C. Gouaillard, and B. Rubin. 2001. Molecular modeling and endoplasmic reticulum retention of mutated TCR/CD3 complexes. Scand. J. Immunol. 53:540.
32. Klein, G., and T. Boon. 1993. Tumor immunology: present perspectives. Curr. Opin. Immunol. 5:3961.
33. Rammensee, H. G., J. Bachmann, N. P. N. Emmerich, O. A. Bachor, and S. Stevanovic. 1999. SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics 50:213.
34. Xu, Y., S. J. Gendler, and A. Franco. 2004. Designer glycopeptides for cytotoxic T cell-based elimination of carcinomas. J. Exp. Med. 199:707.
35. Van Pel, A., P. van der Bruggen, P. G. Coulie, V. G. Brichard, B. Lethé, B. van den Eynde, C. Uyttenhove, J. C. Renauld, and T. Boon. 1995. Genes coding for tumor antigens recognized by cytotoxic T lymphocytes. Immunol. Rev. 145:229.
36. Ikeda, H., N. Ohta, K. Furukawa, H. Miyazaki, L. Wang, K. Furukawa, K. Kuribayashi, L. L. Old, and H. Shiku. 1997. Mutated mitogen-activated protein kinase: a tumor rejection antigen of mouse sarcomas. Proc. Natl. Acad. Sci. USA 94:6375.
37. Berger, C. L., J. Longley, D. Hanlon, M. Girardi, and R. Edelson. 2001. The clonotypic T cell receptor is a source of tumor-associated antigens in cutaneous T cell lymphoma. Ann. NY Acad. Sci. 941:106.
38. Lambert, S. L., C. Y. Okada, and R. Levy. 2004. TCR vaccines against a murine T cell lymphoma: a primary role for antibodies of the IgG2c class in tumor protection. J. Immunol. 172:929.
39. Markiewicz, M. A., and T. F. Gajewski. 1999. The immune system as anti-tumor sentinel: molecular requirements for an anti-tumor immune response. Crit. Rev. Oncog. 10:247.
40. + cytotoxic T lymphocyte-mediated lysis. J. Immunol. 150:4303.